AI Analysis
AI-generated analysis. Always verify with the original filing.
Ultragenyx Pharmaceutical Inc. announced that the FDA has accepted for review its resubmitted Biologics License Application for UX111 gene therapy for Sanfilippo syndrome Type A, with a PDUFA action date of September 19, 2026.
Key Takeaways
1FDA accepted for review the resubmitted Biologics License Application for UX111 gene therapy for Sanfilippo syndrome Type A.
2The FDA set a Prescription Drug User Fee Act action date of September 19, 2026.
3The company is seeking accelerated approval for UX111.
4The press release contains forward-looking statements about the development, regulatory review, and potential approval of UX111.
5Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially.